Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Ter Arkh ; 94(2): 160-165, 2022 Feb 15.
Artículo en Ruso | MEDLINE | ID: mdl-36286738

RESUMEN

AIM: To assess of the ten-year dynamics of cases of hospitalizations of patients with peptic ulcer disease (PUD), chronic gastritis and chronic duodenitis relative to the total number of people treated in the gastroenterological departments of the hospital in 20102019. MATERIALS AND METHODS: Data of the annual reports of the work of the hospital departments were studied retrospectively. RESULTS: The relative number of persons hospitalized for chronic duodenitis decreased 2.8 times (p0.001), but the proportion of patients with chronic gastritis did not tend to decrease. This is most likely due to diagnostic errors. The cases of hospitalization of persons with uncomplicated PUD decreased by 3.1 times (p0.001), the proportion of men with duodenal ulcer decreased by 6.3 times (p0.001), with gastric ulcer decreased 1.9 times (p0.01). The proportion of women hospitalized with duodenal ulcer decreased 2.3 times (p0.01). The number of hospitalized men with duodenal ulcer is 3.8 times more than females (p0.001). It can be explained by a decrease in social stressful influences and active anti-Helicobacter pylori therapy. CONCLUSION: Over the period of follow-up, the cases of hospitalization of patients with uncomplicated PUD decreased, primarily due to a decrease in the proportion of persons with ulcer of the duodenum and duodenitis, while the number of patients with chronic gastritis not undergoing modern examination did not have significant dynamics.


Asunto(s)
Úlcera Duodenal , Duodenitis , Gastritis , Infecciones por Helicobacter , Úlcera Péptica , Masculino , Humanos , Femenino , Duodenitis/diagnóstico , Duodenitis/epidemiología , Duodenitis/complicaciones , Úlcera Duodenal/diagnóstico , Úlcera Duodenal/epidemiología , Gastritis/diagnóstico , Gastritis/epidemiología , Estudios Retrospectivos , Úlcera Péptica/diagnóstico , Úlcera Péptica/epidemiología , Úlcera Péptica/complicaciones , Hospitalización , Enfermedad Crónica , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/epidemiología
2.
Ter Arkh ; 94(1): 48-56, 2022 Jan 15.
Artículo en Ruso | MEDLINE | ID: mdl-36286919

RESUMEN

BACKGROUND: Recently, there has been an increase in the prevalence of gastroesophageal reflux disease (GERD) in Northern Europe, North America and East Asia. However data on GERD prevalence in Russian population are very limited. AIM: To determine the prevalence of GERD among the population of Russia, the clinical spectrum of GERD symptoms, the main drugs used for GERD treatment, and the rate of their administration. MATERIALS AND METHODS: The study was conducted from November 2015 to January 2017 in 8 cities of Russia. A survey of patients over the age of 18 years old visiting outpatient medical institutions for any reason, including patients without gastrointestinal complaints was carried out using a short version of the Mayo Clinic questionnaire. RESULTS: In total, 6132 questionnaires of patients aged 1890 years were analyzed [2456 men (40.1%) and 3676 women (59.9%), mean age 46.615.4 years]. The GERD prevalence among the interviewed patients was 34.2%. The incidence of GERD increased depending on body mass index and the age of the patients. Medications used by the patients for heartburn relief included proton pump inhibitors 59.96%, antacids 67.92%, H2-histamine receptor blockers 11.42%, alginates 18.41% of patients. CONCLUSION: The results of this study indicate a high prevalence of GERD among residents of Russian cities applying for primary health care (34.2%). In comparison with previous studies, an increase in the proportion of GERD patients taking proton pump inhibitors was noted; in most cases the regimen of their intake was in accordance with the recommendations.


Asunto(s)
Antiácidos , Reflujo Gastroesofágico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antiácidos/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Reflujo Gastroesofágico/epidemiología , Reflujo Gastroesofágico/diagnóstico , Pacientes Ambulatorios , Prevalencia , Inhibidores de la Bomba de Protones/uso terapéutico , Bombas de Protones/uso terapéutico , Receptores Histamínicos , Federación de Rusia/epidemiología , Encuestas y Cuestionarios
3.
Ter Arkh ; 91(2): 16-24, 2019 Feb 15.
Artículo en Ruso | MEDLINE | ID: mdl-32598623

RESUMEN

The multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group (EHMSG) is conducted in 27 countries in Europe. The data from the Russian part of the European registry for the management of Helicobacter pylori infection (European Registry on the management of Helicobacter pylori infection, protocol: "Hp-EuReg") allows us to analyze the real clinical practice of diagnosis and treatment of H. pylori and compare it with international recommendations. MATERIALS AND METHODS: A comparative analysis of the data entered in the register by the Russian research centers "Hp-EuReg", in the period from 2013 to 2018, was conducted. RESULTS AND DISCUSSION: Invasive diagnostic methods prevail for the primary diagnosis of H. pylori [histology - 20.3% (in 2013 year) - 43.9% (in 2018 year), rapid urease test - 31.7% and 47.8% respectively]. The most popular mode of eradication therapy is a 10-day triple therapy (62.8-76.2%), the effectiveness of which does not exceed 79% (per protocol). Invasive tests (histology) are the leading method for control the effectiveness of therapy, however, there is a tendency towards a wider use of non-invasive methods (H. pylori stool antigen - from 17% in 2013 to 29.3% in 2018 and urea breath test from 6.9 to 18.3%, respectively). Serological test to control the effectiveness of eradication is still used from 8.2% (2013) to 6.1% (2018). Eradication therapy was not performed in 28% of patients throughout the entire observation period. CONCLUSION: In Russia, despite approved domestic and international recommendations, deviations in clinical practice persist, both during eradication therapy and in monitoring the effectiveness of eradication therapy.


Asunto(s)
Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Antígenos Bacterianos/análisis , Pruebas Respiratorias/métodos , Quimioterapia Combinada/métodos , Heces/microbiología , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/aislamiento & purificación , Antibacterianos/administración & dosificación , Antiulcerosos/administración & dosificación , Quimioterapia Combinada/efectos adversos , Europa (Continente) , Infecciones por Helicobacter/epidemiología , Helicobacter pylori/inmunología , Humanos , Estudios Prospectivos , Sistema de Registros , Federación de Rusia/epidemiología
4.
Ter Arkh ; 90(4): 17-20, 2018 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-30701869

RESUMEN

AIM: Determination of the prevalence of Helicobacter pylori infection (H. pylori) among the urban population. MATERIALS AND METHODS: 655 people (638 adults and 17 children) were examined using the immunoassay method of quantitative detection of IgG class antibodies. RESULTS: High infection of adult residents of Ryazan H. pylori - 64,4% is established. The greatest prevalence of H. pylori infection was observed in individuals 41 to 80 years of age (66,9%). Discovered gender differences in the prevalence of H. pylori infection in persons older than 40 years. H. pylori infection in males aged 41-80 was 76.3%, compared with 65.3% in females (p=0.02). In children 4-15 years, the proportion of persons with positive serological test anti-H. pylori IgG reached 23.5%. All H. pylori infected children were over 9 years of age. 90% of adults with H. pylori infection was detected, isolated or concomitant gastrointestinal symptoms of indigestion. More often, H. pylori infection was associated with abdominal pain - 48.3% (p=0.005) and heartburn - 27% (p=0.04). CONCLUSION: The data obtained indicate a high proportion of H. pylori infection in the adult population in Ryazan - 64,4%. The incidence of detection of anti-H. pylori IgG in the population maximum from individuals 41 to 80 years of age (66,9%).


Asunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Población Urbana , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antibacterianos , Niño , Femenino , Infecciones por Helicobacter/epidemiología , Helicobacter pylori/aislamiento & purificación , Humanos , Inmunoglobulina G , Masculino , Persona de Mediana Edad , Prevalencia
5.
Ter Arkh ; 90(2): 35-42, 2018 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-30701770

RESUMEN

AIM: European Registry on the management of Helicobacter pylori infection («Hp-EuReg¼) - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations. MATERIALS AND METHODS: The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg¼ in 2013-2017, who were underwent 1st line eradication therapy. RESULTS: The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. CONCLUSION: Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.


Asunto(s)
Antibacterianos , Infecciones por Helicobacter , Inhibidores de la Bomba de Protones , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Claritromicina , Quimioterapia Combinada , Europa (Continente) , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Humanos , Estudios Prospectivos , Inhibidores de la Bomba de Protones/uso terapéutico , Sistema de Registros
6.
Ter Arkh ; 88(2): 33-38, 2016.
Artículo en Ruso | MEDLINE | ID: mdl-27030181

RESUMEN

AIM: To assess the clinical practice of diagnosis and treatment in patients with Helicobacter pylori infection and to compare this practice with the international guidelines in the European Registry on the management of Helicobacter pylori infection, Hp-EuReg protocol), a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group. MATERIALs AND METHODS: The data of 813 patients infected with H. pylori and entered in the Hp-EuReg register by the Russian centers in 2013-2015 were analyzed. RESULTS: The most common methods for the primary diagnosis of H. pylori infection are histology (40.3%), rapid urease test (35.7%), and serology (17.2%). The duration of H. pylori eradication therapy was 7, 10, and 14 days in 18.0, 49.3, and 25.1%, respectively. To monitor the effectiveness of treatment, the investigators used a histological examination (34%), a urea breath test (27.3%), H. pylori stool antigen (22.8%), and a rapid urease test (16.3%). A serological test was carried out in 2.5% of the cases. No monitoring was done in 13.5% of the patients. The average eradication efficiency was 82.6%. If the therapy was ineffective, 80% of physicians did not intend to prescribe a new cycle of treatment. CONCLUSION: Significant differences were found between clinical practice and the current guidelines.


Asunto(s)
Antibacterianos/uso terapéutico , Enfermedades Gastrointestinales , Infecciones por Helicobacter , Helicobacter pylori , Inhibidores de la Bomba de Protones/uso terapéutico , Adulto , Pruebas Respiratorias/métodos , Protocolos Clínicos , Europa (Continente)/epidemiología , Femenino , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/epidemiología , Enfermedades Gastrointestinales/terapia , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/fisiopatología , Infecciones por Helicobacter/terapia , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Procesos y Resultados en Atención de Salud , Sistema de Registros/estadística & datos numéricos , Federación de Rusia/epidemiología , Sensibilidad y Especificidad , Ureasa/análisis
7.
Ter Arkh ; 87(2): 45-48, 2015.
Artículo en Ruso | MEDLINE | ID: mdl-25864348

RESUMEN

AIM: To elaborate the normative values of peripheral electrical gastroenterocolonography (EGECG). SUBJECTS AND METHODS: Fifty apparently healthy young people (14 women and 36 men; mean age 20.2 ± 4.7 years) were examined. Peripheral EGECG was used to study the motor-evacuating function of the gastrointestinal tract (GIT). RESULTS: The values of the main indicators and coefficients of GIT electrical activity were defined; the concepts of normal physiological values for GIT electrical activity were identified and their values were determined. CONCLUSION: Peripheral EGECG makes it possible to significantly estimate the bioelectrical activity of the gut. The informative markers of peripheral EGECG are relative electrical activity, ratio coefficient, rhythmicity coefficient, as well as the average amplitude and frequency of bioelectrical activity.


Asunto(s)
Técnicas de Diagnóstico del Sistema Digestivo/normas , Fenómenos Electrofisiológicos/fisiología , Adulto , Técnicas de Diagnóstico del Sistema Digestivo/instrumentación , Femenino , Humanos , Masculino , Valores de Referencia , Adulto Joven
8.
Eksp Klin Gastroenterol ; (9): 44-7, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-25916133

RESUMEN

There was installed a significant positive relationship between body mass index (BMI) and the velocity of cicatrization of ulcer in patients with ulcer disease (PUD) with trophological violations. Change in the index ratio of lymphocytes and ESR in patients with PUD trophological violations can be used to predict the velocity of cicatrization of ulcer. The general maladjustment more often observed in patients (PUD) underweight.


Asunto(s)
Adaptación Fisiológica/fisiología , Índice de Masa Corporal , Repitelización , Úlcera Gástrica/diagnóstico , Adulto , Sedimentación Sanguínea , Tamaño Corporal , Estudios de Casos y Controles , Femenino , Humanos , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Úlcera Gástrica/sangre , Úlcera Gástrica/etiología , Úlcera Gástrica/fisiopatología , Adulto Joven
9.
Eksp Klin Gastroenterol ; (10): 28-32, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-25911927

RESUMEN

Conducted clinical and experimental study showed the effectiveness of the use of essential phospholipids as hepatoprotector alcohol-related liver diseases. The application of essential phospholipids reduces the morphological severity of inflammatory and degenerative changes in the liver, improves the clinical picture and laboratory status of patients.


Asunto(s)
Alcoholismo/complicaciones , Hepatopatías Alcohólicas/tratamiento farmacológico , Fosfatidilcolinas/uso terapéutico , Adolescente , Adulto , Anciano , Alcoholismo/sangre , Alcoholismo/tratamiento farmacológico , Alcoholismo/patología , Animales , Femenino , Humanos , Hepatopatías Alcohólicas/sangre , Hepatopatías Alcohólicas/etiología , Hepatopatías Alcohólicas/patología , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Fosfatidilcolinas/administración & dosificación , Ratas Wistar , Resultado del Tratamiento , Adulto Joven
10.
Eksp Klin Gastroenterol ; (5): 36-41, 2013.
Artículo en Ruso | MEDLINE | ID: mdl-24501945

RESUMEN

Despite the identical content of mebeverine hydrochloride, Duspatalin and Niaspam, produced by different technological processes, can't be considered interchangeable as they are known to have different clinical effect in case of various functional diseases of alimentary organs. Duspatalin is effective in relieving biliary disfunction symptoms, Oddy's sphincter hypertonicity in particular, but has little effect on intestinal dyskinesia. Niaspam is known to have little effect on biliary dyskinesia, but has a prominent positive clinical effect on intestinal dyskinesia.


Asunto(s)
Discinesia Biliar/tratamiento farmacológico , Enfermedades Intestinales/tratamiento farmacológico , Parasimpatolíticos/administración & dosificación , Fenetilaminas/administración & dosificación , Adulto , Discinesia Biliar/fisiopatología , Femenino , Humanos , Enfermedades Intestinales/fisiopatología , Masculino , Persona de Mediana Edad
12.
Ter Arkh ; 83(1): 45-50, 2011.
Artículo en Ruso | MEDLINE | ID: mdl-21446202

RESUMEN

AIM: To assess prevalence of gastroesophageal reflux disease (GERD) in Russia in MEGRE trial in 6 cities of the Russian Federatiion (Kazan, Kemerovo, Krasnoyarsk, Ryazan, St-Petersburg, Saransk). MATERIAL AND METHODS: Mayo Clinic questionnaire (USA) adapted for Russia was used to question 7812 people over 18 years of age from of random population sample. The symptoms (heartburn and regurgitation) were classified as frequent if they arose once a week and more often for the last 12 months, rare symptoms arose less often than once a week. The responders with frequent heartburn and/or regurgitation were regarded as persons with epidemiological quantitative criteria of GERD. RESULTS: Heartburn occurred in 47.5% responders: frequent in 9%, rare in 38.5%. Regurgitation occurred in 42.9%: frequent in 7.6%, rare in 35.3%. GERD prevalence was 13.3% (city range 11.3-14.3%). Frequent GERD symptoms are associated with frequent gaseous eructation (24.3%), chronic cough (22.9%), chest pain (15.1%), dysphonia (11.4%.). To stop heartburn, 88% responders took antacids, 32%--blockers of histamine H2-receptors and only 23%--inhibitors of proton pump. Only 52.8% responders with frequent chest pain and 29.3% those with frequent heartburn visited a doctor. CONCLUSION: The population-based trial MEGRE conducted by international methodology in 6 cities of Russia demonstrated that GERD prevalence is 13.3%. Most of the patients pay little attention to the symptoms, do not seek medical advice and, therefore, receive no adequate treatment.


Asunto(s)
Reflujo Gastroesofágico/epidemiología , Vigilancia de la Población , Adolescente , Adulto , Factores de Edad , Anciano , Femenino , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Federación de Rusia/epidemiología , Encuestas y Cuestionarios , Adulto Joven
13.
Eksp Klin Gastroenterol ; (6): 70-6, 2010.
Artículo en Ruso | MEDLINE | ID: mdl-20731169

RESUMEN

Was conducted a muIticenter study VIA APIA, in which the impact of gaviscon forte (suspension) on symptoms, general state and quality of life of 148 patients (male 53, female 95, age 42.9 +/- 15.6) with gastroesophageal reflux disease (GERD) were investigated. The patients had undergone clinical evaluation of dynamics of GERD symptoms (Likert scale), general state (Visual Analogue Scale, questionnaire SAN) and quality of life (SF-36). It was shown that 14-days treatment with gaviscon forte provided symptoms relief in 84.5% patients and conducted improvement of general state and quality of life. Gaviscon forte recommended as drug of choice in initial treatment for the first time visited patient with heartburn before endoscopy and for pathogenetic treatment of typical reflux syndrome.


Asunto(s)
Alginatos/uso terapéutico , Hidróxido de Aluminio/uso terapéutico , Antiácidos/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Pirosis/tratamiento farmacológico , Calidad de Vida , Ácido Silícico/uso terapéutico , Bicarbonato de Sodio/uso terapéutico , Adulto , Alginatos/administración & dosificación , Hidróxido de Aluminio/administración & dosificación , Antiácidos/administración & dosificación , Combinación de Medicamentos , Femenino , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/prevención & control , Reflujo Gastroesofágico/psicología , Pirosis/diagnóstico , Pirosis/prevención & control , Pirosis/psicología , Humanos , Masculino , Estudios Prospectivos , Calidad de Vida/psicología , Índice de Severidad de la Enfermedad , Ácido Silícico/administración & dosificación , Bicarbonato de Sodio/administración & dosificación , Encuestas y Cuestionarios , Suspensiones , Resultado del Tratamiento
14.
Eksp Klin Gastroenterol ; (1): 33-7, 2009.
Artículo en Ruso | MEDLINE | ID: mdl-19548420

RESUMEN

Was developed screening test for early diagnosis of various biliary dysfunction. It is based on determining of elektrodermal resistance and temperature of skin in biologically active points. A new method of diagnosis hasn't contraindications, not require the use of expensive or complicated equipment.


Asunto(s)
Discinesia Biliar/diagnóstico , Electrodiagnóstico/métodos , Fenómenos Fisiológicos de la Piel , Termografía/métodos , Discinesia Biliar/fisiopatología , Diagnóstico por Computador , Impedancia Eléctrica , Femenino , Humanos , Masculino , Temperatura Cutánea/fisiología
15.
Eksp Klin Gastroenterol ; (6): 4-12, 2009.
Artículo en Ruso | MEDLINE | ID: mdl-20205320

RESUMEN

We aimed to determine the prevalence and clinical spectrum of GERD in the urban population of 6 cities in different parts of Russia (St. Petersburg, Ryazan, Kazan, Kemerovo, Krasnoyarsk and Saransk). A previously validated reflux questionnaire developed at the Mayo Clinic was translated into Russian, culturally adapted and administered. Data was collected from 7812 randomly selected subjects greater than 18 years old with the assistance of the yellow pages. 'Frequent symptoms' were defined as a major symptom (heartburn and/or regurgitation) occurring at least once a week or more. "Occasional symptoms" were defined as an episode of one of the major symptoms occurring less than once a week within the past 12 months. Patients were defined as having GERD if they reported frequent heartburn and/or regurgitation. The average prevalence of frequent and occasional GERD symptoms in Russia was 9% and 38.5% for heartburn and 7.6% and 35.3% for regurgitation respectively within the last 12 months. The average prevalence of GERD in Russia was 13.3% (11.3-14.3%). The prevalence of frequent heartburn decreased with age (r = -0.3); however, frequent regurgitation increased (r = 0.7) with age. As a result, we found that prevalence of GERD increased with age. The average prevalence of GERD was statistically the same in men (12.5%) and in women (13.9%). This prevalence didn't change with age in men but did increase with age in elderly women to 24%. Frequent heartburn and regurgitation (GERD) were significantly associated with frequent belching (24.3%), chronic cough (22.9%), dyspepsia (19.8%), non-cardiac chest pain (15.1%), nausea (14.9%), hoarseness (11.4%), dysphagia (8.1%), odynophagia (7.3%) and constipation (37.8%). Alcohol consumption (prevalence of 60.4% among respondents) and smoking (prevalence of 25.4% among respondents) didn't yield any significant difference in subjects with frequent symptoms. Importantly, we also found that only 52.8% of subjects with frequent chest pain and 29.3% of respondents with frequent heartburn had seen a physician for these symptoms.


Asunto(s)
Reflujo Gastroesofágico/epidemiología , Encuestas y Cuestionarios , Adulto , Factores de Edad , Anciano , Dolor en el Pecho/epidemiología , Dolor en el Pecho/fisiopatología , Tos/epidemiología , Tos/fisiopatología , Dispepsia/epidemiología , Dispepsia/fisiopatología , Eructación/epidemiología , Eructación/fisiopatología , Femenino , Reflujo Gastroesofágico/fisiopatología , Pirosis/epidemiología , Pirosis/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Federación de Rusia/epidemiología
17.
Adv Gerontol ; 18: 86-9, 2006.
Artículo en Ruso | MEDLINE | ID: mdl-16676803

RESUMEN

The study of peculiarity a tone of vegetative nervous system at patients of different age with ulcer defeats of a stomach, types of temperament, a level of neurotics, expressiveness introversion and extraversion. WE USED: Modified Eysenk Personality Questionnaire, EGG, standard vegetative test CITO (SVT CITO). OUR RESULTS: Rise of neurotic level in patients with stomach ulcer, indications of vegetative distones with characteristic apportionment of activity of VNS. Reflexotherapy, carry on counting variation of tone VNS expedite scaring of ulcer defeat.


Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/terapia , Reflejoterapia/métodos , Úlcera Gástrica/complicaciones , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Enfermedades del Sistema Nervioso Autónomo/etiología , Enfermedades del Sistema Nervioso Autónomo/psicología , Humanos , Masculino , Persona de Mediana Edad , Pruebas Psicológicas , Úlcera Gástrica/psicología , Úlcera Gástrica/terapia
18.
Klin Med (Mosk) ; 83(11): 69-71, 2005.
Artículo en Ruso | MEDLINE | ID: mdl-16404945

RESUMEN

The aim of the study was to evaluate the influence of non-invasive laser therapy on the efficacy of gastric ulcer therapy. The study revealed shortening of the time to ulcer cicatrization in patients who were treated with laser emission of the organospecific iridic zones and immunocompetent body parts in addition to standard drug therapy.


Asunto(s)
Terapia por Luz de Baja Intensidad/métodos , Úlcera Gástrica/radioterapia , Antiulcerosos/uso terapéutico , Biopsia , Endoscopía Gastrointestinal , Estudios de Seguimiento , Mucosa Gástrica/patología , Mucosa Gástrica/efectos de la radiación , Humanos , Persona de Mediana Edad , Úlcera Gástrica/tratamiento farmacológico , Úlcera Gástrica/patología , Resultado del Tratamiento
19.
Adv Gerontol ; 14: 96-100, 2004.
Artículo en Ruso | MEDLINE | ID: mdl-15559506

RESUMEN

The existent methods of treatment patient with ulcer of gastroduodenal zone provide treatment of ills in correspondence with "Standards..." and don't take into account age features of patient. For increase efficiency of treatment patient with gastric ulcer taking into account infection Helicobacter pylori, age features a patient, we conduct the treatment 612 ills using eradication therapy, laser therapy, needlereflexotherapy. We made deduction that eradicates Helicobacter pylori increases time of remission of disease. The needlereflexotherapy conducting with using our methods measures spud of cicatrisation gastric ulcer, especially in cases with the elderly ills. The laser therapy conducting with using our methods especially increases speed of cicatrisation gastric ulcer in cases with the elderly ills, too.


Asunto(s)
Terapia por Acupuntura/métodos , Infecciones por Helicobacter/tratamiento farmacológico , Terapia por Luz de Baja Intensidad/métodos , Úlcera Gástrica/terapia , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Terapia Combinada , Femenino , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Humanos , Masculino , Persona de Mediana Edad , Úlcera Gástrica/microbiología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda